Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $86.23, for a total value of $370,961.46.

Palvella Therapeutics Stock Performance

PVLA traded up $3.49 during midday trading on Friday, reaching $99.73. 957,735 shares of the company were exchanged, compared to its average volume of 138,431. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -37.92 and a beta of -0.20. Palvella Therapeutics, Inc. has a one year low of $11.17 and a one year high of $112.00. The company’s fifty day moving average price is $85.21 and its 200 day moving average price is $56.66.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PVLA. Cantor Fitzgerald boosted their price target on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Canaccord Genuity Group lifted their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $193.00 target price on shares of Palvella Therapeutics in a report on Tuesday. Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday. Finally, Chardan Capital lifted their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics currently has an average rating of “Buy” and a consensus price target of $155.60.

Institutional Investors Weigh In On Palvella Therapeutics

Large investors have recently added to or reduced their stakes in the company. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $28,000. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics during the third quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Palvella Therapeutics in the second quarter worth about $37,000. JPMorgan Chase & Co. boosted its position in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $85,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics News Summary

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Oppenheimer raised its price target to $200 from $120, a strong signal from a sell‑side firm that can boost bullish interest. Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer
• Positive Sentiment: TD Cowen raised its price target to $133, adding further upward pressure on the stock via another institutional endorsement. TD Cowen Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00
• Positive Sentiment: Market headlines note an analyst upgrade that coincided with a recent sharp move higher in PVLA shares, which likely amplified buying momentum. Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% After Analyst Upgrade
• Neutral Sentiment: HC Wainwright revised down near‑term EPS forecasts for FY2027–FY2029 (multiple cuts) but kept a “Buy” rating and a $200 price target — a mixed signal that tempers long‑term optimism with weaker near‑term profitability projections.
• Negative Sentiment: Lifesci Capital cut its FY2026 EPS estimate (worse expected losses), a negative revision that could weigh on sentiment if the company misses near‑term expectations.
• Negative Sentiment: COO Kathleen Goin sold 4,302 shares at an average price of $96.47 (SEC filing), a disclosure investors often view as a cautionary sign even if the sale may be for personal reasons. SEC filing

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.